FDANews
FDAnews Drug Daily Bulletin

INYX'S EXAERIS, INC. AND ACCENTIA BIOPHARMACEUTICALS, INC. SIGN CO-PROMOTION AGREEMENT FOR MD TURBO

April 13, 2006

Exaeris, Inc., a wholly owned subsidiary of Inyx, Inc., and TEAMM Pharmaceuticals, Inc., the specialty pharmaceutical division of Accentia BioPharmaceuticals, Inc., announced today that they have finalized a co-promotion agreement through which the companies will co-market the MD Turbo, a novel breath-activated, dose-counting companion to meter dose inhalers (MDIs). MD Turbo will be available by prescription in the U.S. later this quarter.
PR Newswire